Glaxosmithkline Regulatory News (GSK)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 April 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.4100

956

£17.4100

768

£17.4100

639

d)

Aggregated information

Aggregated volume Price

2,363

£17.4100

e)

Date of the transaction

2022-04-08

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr I Mackay

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 April 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.4100

661

£17.4100

518

£17.4100

443

d)

Aggregated information

Aggregated volume Price

1,622

£17.4100

e)

Date of the transaction

2022-04-08

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr H Barron

b)

Position/status

Chief Scientific Officer and President, R&D

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

b)

Nature of the transaction

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 7 April 2022 on ADSs held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$46.2300

523

$46.2300

437

$46.2300

331

d)

Aggregated information

Aggregated volume Price

1,291

$46.2300

e)

Date of the transaction

2022-04-08

f)

Place of the transaction

New York Stock Exchange (XNYS)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R Connor

b)

Position/status

President, Vaccines and Global Health

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 April 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.4100

162

£17.4100

242

£17.4100

140

d)

Aggregated information

Aggregated volume Price

544

£17.4100

e)

Date of the transaction

2022-04-08

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms D Conrad

b)

Position/status

Chief People Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 April 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.4100

150

£17.4100

99

£17.4100

92

d)

Aggregated information

Aggregated volume Price

341

£17.4100

e)

Date of the transaction

2022-04-08

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr J Ford

b)

Position/status

SVP and Group General Counsel, Legal and Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 April 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.4100

184

£17.4100

142

£17.4100

111

d)

Aggregated information

Aggregated volume Price

437

£17.4100

e)

Date of the transaction

2022-04-08

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms S Jackson

b)

Position/status

SVP, Global Communications and CEO Office

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 April 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.4100

86

£17.4100

60

£17.4100

56

d)

Aggregated information

Aggregated volume Price

202

£17.4100

e)

Date of the transaction

2022-04-08

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr B McNamara

b)

Position/status

CEO, GSK Consumer Healthcare

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

b)

Nature of the transaction

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 7 April 2022 on ADSs held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$46.2300

55

$46.2300

80

$46.2300

101

d)

Aggregated information

Aggregated volume Price

236

$46.2300

e)

Date of the transaction

2022-04-08

f)

Place of the transaction

New York Stock Exchange (XNYS)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr L Miels

b)

Position/status

Chief Commercial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 April 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.4100

314

£17.4100

232

£17.4100

173

d)

Aggregated information

Aggregated volume Price

719

£17.4100

e)

Date of the transaction

2022-04-08

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms S Ramakrishnan

b)

Position/status

Chief Digital and Technology Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

b)

Nature of the transaction

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 7 April 2022 on ADSs held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$46.2300

31

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-04-08

f)

Place of the transaction

New York Stock Exchange (XNYS)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 April 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.4100

208

£17.4100

170

£17.4100

136

d)

Aggregated information

Aggregated volume Price

514

£17.4100

e)

Date of the transaction

2022-04-08

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R Simard

b)

Position/status

President, Pharmaceuticals Supply Chain

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 April 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.4100

189

£17.4100

120

£17.4100

102

d)

Aggregated information

Aggregated volume Price

411

£17.4100

e)

Date of the transaction

2022-04-08

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 April 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.4100

131

£17.4100

98

£17.4100

79

d)

Aggregated information

Aggregated volume Price

308

£17.4100

e)

Date of the transaction

2022-04-08

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms D Waterhouse

b)

Position/status

CEO, ViiV Healthcare

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 April 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.4100

138

£17.4100

163

d)

Aggregated information

Aggregated volume Price

301

£17.4100

e)

Date of the transaction

2022-04-08

f)

Place of the transaction

London Stock Exchange (XLON)